3499cc拉斯维加斯(官网VIP入口)-The best platform

Risen Pharma

A clinical stage group with innovative drug research and development capability and international competitiveness

Committed to clinical urgent, patient accessible drug R&D and commercialization. The Group has two R&D centers (with a total square footage of nearly 9000m²), which are located in the hub of Shanghai Zhangjiang Hi-Tech Park and Suzhou Industrial Park, and invested in the construction of a manufacturing site covering 55 acres of land in the Life Blue Bay of Lingang,. The Group has nearly 20 new drug research and development pipelines, focusing on drug R&D in the three core therapeutic areas of orthopedics, oncology and neuroscience, and dedicated R&D investment in the field of siRNA.

Risen Pharma

A clinical stage group with innovative drug research and development capability and international competitiveness

Corporate Culture

People-centered

To serve the patients, Risen built a team as the driving force for innovation. With the strong support of investors, together with partners and suppliers, we are committed to providing doctors with diversified therapeutics to benefit human beings.

Team

Doctor

Investor

Partners

Supplier

Patient

Accept Challenges Pursue Excellence Persist in innovation Technological innovation first R&D efficiency first People development first

Development History

2015

2019

2020

2021

2022

2023

2015.07

Incorporation of the Company

2015.08

Series A Funding - RMB 53.6 million

2015.12

Suzhou Lab Opens

2019.02

Risen-TopAlliance Cooperation - RMB 300 million

2019.07

Executives from Orthopedics and Clinical Medicine Join.

2019.10

Suzhou Lab Undergoes Two Expansions

2020.05

Executives from Drug Development and Pharmaceutical Chemistry Join.

2020.07

RP903 FDA P-IND

2020.12

RP901 CDE IND

2020.12

B Round Funding - RMB 374 Million

2021.03

RP901 Clinical Phase I SAD

2021.09

Acquisition of 56 mu of land in Lingang Area

2021.10

RP902 CDE P-IND

2021.12

RP903 CDE P-IND

2021.12

RP901 FDA IND

2022.03

RP903 CDE IND

2022.05

RP901 临床I期 MAD

2022.06

RP904 CDE P-IND

2022.06

RP903 FDA IND

2022.06

首席科学官CSO、生物高管加入

2022.06

张江研发中心竣工

2023.2

First in China: ANGPTL3 siRNA drug
clinical trial

2023.2

RP904 tablets have obtained approval for clinical trials from the NMPA.

2023.3

Risen was entitled as a "special and innovative" small to medium-sized

Management Team

Jiasheng Lv, Ph.D.

Founder、CEO

Details

Xianqi Kong, Ph.D.

Senior Vice President

Details

Tianlun Zhou, Ph.D.

Vice President, Biology

Details

Dawei Chen, Ph.D.

Vice President，Chemistry

Details

mei-shu.shi, Ph.D.

Vice President，Orthopedics and Pathology.

Details

Ji Jiang, Ph.D.

Vice President，Clinical Medicine

Details

Emma Saffman, Ph.D.

Vice President，Intellectual property

Details

Partners

The joint R&D of small molecule drugs by TopAlliance and Risen in the field of anti-tumor therapy complements the small molecule anti-tumor drug development pipeline of TopAlliance, while conducive to the exploration of Mab drug combination therapy in the future.

Jiasheng Lv, Ph.D.

Founder、CEO

With nearly 15 years of drug research experience, Dr. Lv has led a number of Class 1 innovative drug projects and is an inventor of several clinical drug compounds. Among them, the new drug project for Alzheimer's disease is in phase III clinical research in the United States (orphan drug, fast-track approval); He served as a professor at the Beijing Institute of Technology and led a number of national key projects. He is also a visiting professor of Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences.

Xianqi Kong, Ph.D.

Senior Vice President

With nearly 30 years of drug research and development experience, hundreds of international patents, Dr. Kong has wealth of intellectual property application, protection experience. He previously served as Director of Pharmacy at Bellus Health Inc. (TSX:BLU), a publicly traded Canadian biotechnology company, and was the first inventor of several clinical experimental compounds.

Tianlun Zhou, Ph.D.

Vice President, Biology

With nearly 30 years of drug research and development experience, especially in RNA drugs and anti-HBV drug R&D, Dr. Zhou is proficient in medicine, cancer epidemiology, molecular biology, data mining and pathway analysis and other fields. He was previously head of antiviral drug development and translational cancer research at Novartis.

Dawei Chen, Ph.D.

Vice President，Chemistry

Dr. Chen has been engaged in the research and development of small molecule drugs for nearly 20 years, and discovered a number of clinical compounds in antiviral, immune system diseases and anti-tumor areas. He served as principal scientist at Achillion Pharmaceuticals (Nasdaq:ACHN), a publicly traded pharmaceutical company in US.

mei-shu.shi, Ph.D.

Vice President，Orthopedics and Pathology.

With more than 30 years of drug research and development experience, Dr. Shi is an internationally renowned expert of orthopedics and pathology. He served as the R&D director of several well-known pharmaceutical institutions in the United States, and the former Chief Scientist Officer of Pengli Biomedicine Technology (Shanghai) Co., LTD., supervised over more than 60 new drug application projects domestically and abroad.

Ji Jiang, Ph.D.

Vice President，Clinical Medicine

With nearly 30 years of new drug clinical research experience, Dr. Jiang is a famous clinical research experts in China. He served as a professor and director of the Clinical Pharmacology Center of the Institute of Nuclear Medicine of Peking Union Medical College Hospital, and undertook more than 100 Phase I clinical trials and generic drug equivalence studies as a principal investigator.

Emma Saffman, Ph.D.

Vice President，Intellectual property

With more than 20 years of experience in North American intellectual property protection, Dr. Saffman has expertise in the field of medicine, and the application and evaluation of North American patents, as well as the international management and commercial application of patents. She previously served as Director of Intellectual Property at Bellus Health Inc. (TSX:BLU), a publicly traded Canadian company.